Systematic review and meta-analysis. small intestinal bacterial overgrowth in chronic pancreatitis by Capurso, G et al.
Original Article
Systematic review and meta-analysis: Small
intestinal bacterial overgrowth in chronic
pancreatitis
Gabriele Capurso, Marianna Signoretti, Livia Archibugi, Serena Stigliano and
Gianfranco Delle Fave
Abstract
Background: Evidence on small intestinal bacterial overgrowth (SIBO) in patients with chronic pancreatitis (CP) is
conflicting.
Aim: The purpose of this study was to perform a systematic review and meta-analysis on the prevalence of SIBO in CP and to
examine the relationship of SIBO with symptoms and nutritional status.
Methods: Case-control and cross-sectional studies investigating SIBO in CP patients were analysed. The prevalence of
positive tests was pooled across studies, and the rate of positivity between CP cases and controls was calculated.
Results: In nine studies containing 336 CP patients, the pooled prevalence of SIBO was 36% (95% confidence interval (CI)
17–60%) with considerable heterogeneity (I2¼ 91%). A sensitivity analysis excluding studies employing lactulose breath test
gave a pooled prevalence of 21.7% (95% CI 12.7–34.5%) with lower heterogeneity (I2¼ 56%). The odds ratio for a positive
test in CP vs controls was 4.1 (95% CI 1.6–10.4) (I2¼ 59.7%). The relationship between symptoms and SIBO in CP patients
varied across studies, and the treatment of SIBO was associated with clinical improvement.
Conclusions: One-third of CP patients have SIBO, with a significantly increased risk over controls, although results are
heterogeneous, and studies carry several limitations. The impact of SIBO and its treatment in CP patients deserve further
investigation.
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Background
Chronic pancreatitis (CP) is a challenging disease, char-
acterised by inflammatory and destructive changes of the
pancreas, which can cause significant symptoms, malnu-
trition, reduced quality of life and life-threatening com-
plications.1 Most patients with CP experience symptoms
such as bloating, diarrhoea, cramping and abdominal
pain.2 As some of these symptoms are related with pan-
creatic exocrine insufficiency (PEI), the therapeutic
options for the medical treatment of CP include the
administration of pancreatic enzyme replacement ther-
apy (PERT)2 which leads to a significant reduction of
bloating and diarrhoea.3,4 When symptoms do not
improve with PERT, it has been suggested that there is
a need to rule out other possible causes, including small
intestinal bacterial overgrowth (SIBO).5,6
SIBO is a condition in which the increased bacterial
load in the small bowel results in excessive fermentation
and inflammation, leading to a variety of clinical com-
plaints ranging from mild, non-specific symptoms such
as abdominal pain, bloating, and flatulence, to more
severe manifestations such as malabsorption and
weight loss.7 In patients with CP, a number of factors
such as fat malabsorption, diabetic neuropathy, use of
drugs that affect motility or use of proton pump
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inhibitors, alcohol intake and surgical procedures can
favour the occurrence of SIBO. In clinical practice, glu-
cose or lactulose hydrogen breath tests (GHBT and
LHBT) are the most commonly employed tests for
the diagnosis of SIBO, with GHBT being considered
more accurate than LHBT.8,9
The reported rate of SIBO in CP patients is extre-
mely variable, due to the heterogeneity and several limi-
tations of published studies.10–12 Moreover, as the
clinical manifestation and signs of SIBO can be attrib-
uted to CP itself and, as there is no evidence suggesting
that SIBO might complicate only CP cases unrespon-
sive to PERT, whether all CP patients should be tested
for SIBO, irrespective of symptoms, is uncertain. We,
therefore, aimed at conducting a systematic review and
meta-analysis on the prevalence of SIBO in CP
patients. We also aimed at examining whether the pres-
ence of SIBO was related to symptoms and nutritional
status in CP patients.
Methods
Search strategy and study selection
A computerised literature search of MEDLINE and of
the Cochrane database did not identify any previous
publication related to systematic review on CP and
SIBO. In our search for original studies, we performed
a MEDLINE search (until 25 August 2015). Specific
search terms were: ‘(chronic pancreatitis) AND
(breath tests OR small intestine OR bacterial infections
OR bacterial overgrowth OR lactulose hydrogen OR
glucose hydrogen)’. The methodology was developed
from the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement.13
There were no language restrictions and abstracts of
the articles identified were assessed for appropriateness
to the study question, and all potentially relevant
articles were obtained and evaluated in detail. Hand-
searching of the reference lists of all the included arti-
cles was performed to help retrieving further potentially
relevant studies.
Inclusion/exclusion criteria
Studies were considered if they met the following cri-
teria: (a) age> 18 years; (b) inclusion of patients with a
presumed diagnosis of CP (either according to clinico-
radiological data, physician’s opinion, questionnaire,
or meeting specific diagnostic criteria); (c) investigation
of SIBO by means of any of the following tests or of
their combination: LHBT, GHBT, xylose or sucrose
hydrogen breath tests (BTs), or jejunal aspirate and
culture. (d) either a cross-sectional or case-control
design. Studies were excluded if they were available as
abstract only. We also excluded: (a) case reports; (b)
papers reporting pancreatic disorders different from
CP. Two independent reviewers (LA and MS) carried
out study identification, selection and discussed dis-
agreements with a third reviewer (GC). Excluded stu-
dies and the reasons for exclusion were recorded.
Data extraction and quality assessment
Two reviewers (LA and MS) extracted data from each
study onto a Microsoft Excel spreadsheet (XP
Professional Edition; Microsoft Corp., Redmond,
Washington, USA). From each of the studies that
met the eligibility criteria, the following clinical data
were extracted: country of origin and number of parti-
cipating centers, test used to detect SIBO and criteria
used to define a positive test, diagnostic criteria used to
define CP, source of controls (for case-control studies),
and whether studies excluded individuals that received
surgery before enrollment. The presence of symptoms,
of nutritional deficiencies and their relation to the diag-
nosis of SIBO were also recorded, as well as the effect of
treatment.
The quality of the studies was evaluated independ-
ently by two reviewers (SS and GC) using the
Newcastle–Ottawa Scale. The specific scales for both
case-control and cross-sectional studies14,15 award a
maximum of 10 points to each study, with scores for
items such as the definition of the sample, ascertain-
ment and representativeness of the exposure and stat-
istical analysis. Studies with a score 6 were considered
as high quality studies.
Data synthesis and statistical analysis
The proportion of individuals with CP with a positive
test for SIBO was combined for both cross-sectional
and case-control studies, to give a pooled prevalence
in all individuals meeting diagnostic criteria for CP.
In addition, for case-control studies, data were pooled
for both cases and controls, and the prevalence of a
positive test for SIBO, regardless of the type of test
used, was compared between the two groups to calcu-
late an odds ratio (OR) and 95% confidence interval
(CI).
A meta-analysis of all eligible studies identified was
then performed with the software package
Comprehensive Meta-Analysis (Biostat, Englewood,
New Jersey, USA) using a random-effects model.16,17
In addition to within-study variance, the random-
effects model considers heterogeneity among studies
and gives estimates that are more conservative. We pre-
ferred the random-effects model because we believe that
the relevant variation in the risk is most likely a conse-
quence of inter-study differences. The quantity of
698 United European Gastroenterology Journal 4(5)
heterogeneity was assessed by means of the I2 value.18
The I2 quantity describes the percentage of total vari-
ation across studies that is caused by heterogeneity and
not by chance. We considered an I2 value of 25% or
lower as trivial heterogeneity, and an I2 value of 75% or
higher as considerable heterogeneity. Publication bias
was assessed using the Begg and Mazumdar test.
A p-value <0.05 was accepted as statistically signifi-
cant. Before performing the analysis, we developed
the following a priori hypotheses to examine whether
this had any effect on the prevalence or odds of SIBO
and to explore reasons for any heterogeneity observed:
(a) employed method to diagnose SIBO (GHBT vs
LHBT); (b) inclusion of CP patients that received
previous surgery which can cause SIBO per se; (c) qual-
ity of the study (quality score >6/12 or 6/12).
Results
Search results and study selection
A total of 1604 references were identified by the
MEDLINE search (Figure 1). After evaluation, 1566
studies were excluded, as they were not related to the
study topic. This resulted in 38 studies that were exam-
ined in more detail, 29 of which were considered as
potentially appropriate for inclusion in the review.
However, 20 of them did not fulfill all inclusion criteria.
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram of assessment of studies identified in
the systematic review.
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Finally, nine studies10–12,19–24 remained for qualitative
analysis and quantitative synthesis.
Study characteristics and quality assessment
The descriptive characteristics of the nine included stu-
dies are shown in Table 1. Six studies were from Europe,
two from Asia (India and South Korea) and one from
South America (Chile). English was the language of
seven papers whilst one was in written in Spanish19 and
one in Russian21 There were only single centre studies.
The number of enrolled patients in each study ranged
between 1111 and 102.21 Overall, 336 patients with a diag-
nosis of CP were investigated for SIBO. The rate of male
patients ranged between 34%21 and 100%,11 and the rate
of alcoholic aetiology of CP ranged between 32.3%22 and
100%.11 The rate of patients with PEI was reported in all
but one paper24 and ranged from 31.7%22 to
100%,11,19,20 while the rate of diabetes ranged from
14.3%20 to 66.6%,24 being not reported in one study.21
In three of the nine studies, there were CP patients who
had previously undergone gastrointestinal surgery,10,19,20
which can be a cause of SIBO per se.
Seven studies had a case-control design10–12,19,20,22,24
and the other two were cross-sectional studies,21,23 with
some differences regarding the selection of controls. As
regards the methods employed to determine the diag-
nosis of SIBO (see Table 2), there were no studies
employing jejunal or duodenal aspirate. Six studies
employed glucose as substrate of BT10–12,20,22,23 whilst
three studies used lactulose.19,21,24 In a single study,23
SIBO was evaluated by GHBT, but also by 14
C-cholyl-glycine BT; however, as this last test is far
less commonly employed and standardised, we decided
to analyse only data obtained with glucose BT from
that study. In one paper24 not only the excretion of
hydrogen (H2) in the breath sample, but also that of
methane (CH4) was measured. Furthermore, there was
wide heterogeneity regarding BT protocol in terms of
doses of substrate, duration of the examination, sam-
pling intervals and cut-off for the diagnosis of SIBO
(see Table 2). As far as regards the quality of the
included studies, five of the seven case-control studies
and one of the two cross-sectional studies were scored
as ‘high quality’ (see Supplementary Material, Table 1).
Prevalence of SIBO in patients with CP
The prevalence of a positive BT for SIBO in the nine
individual studies ranged from 14–92%, with a pooled
prevalence of 36% (95% CI 17–60%) (Figure 2). There
was considerable heterogeneity (I2¼ 91%). No publica-
tion bias was found (Begg and Mazudmar Kendall’s
tau¼0.13; p¼ 0.6).We repeated the analysis based on
our a priori hypotheses considering a number of covari-
ates. When we considered the six studies employing
GHBT (Figure 3), the pooled prevalence of SIBO was
21.7% (95% CI 12.7–34.5%) with a lower heterogeneity
(I2¼ 56%). The same analysis on the three studies using
lactulose as substrate for BT, gave a much higher preva-
lence of 73.3% (95% CI 67.4–90.6%) with considerable
heterogeneity (I2¼ 86%). Six of the examined studies did
not include CP patients that had received surgery, which
can be a cause of SIBO per se. The pooled prevalence of
SIBO for these studies was slightly lower than that
observed in the entire set of studies, being 25.7% (95%
CI 8.1–57.6%) (Figure 4) albeit still with considerable
heterogeneity (I2¼ 94%). In the three studies that
included operated patients, the pooled estimate rate
was as high as 54.1% (95% CI 23.2–82.1%) with an
Table 1. Study demographics, population size and characteristics.
First author
(reference) Country
Patients
(n)
Sex
(male %)
Age
(years)
Alcoholic
aetiology
(%) PEI
Diabetes
mellitus
(%)
Pancreatic
calcifications
(%)
Previous
surgery
PERT
(%)
Controls
(n)
Controls
characteristics
Lembcke23 Germany 20 NR NR 90% 95% 40% 65% 0% NR – –
Casellas10 Spain 15 11 (73.3%) Mean 51 73.3% 100% 66.6% 80% 66% 100% 39 Immunodeficiency,
gastroduodenal
surgery
Trespi20 Italy 35 26 (74.2%) Mean 53 54.3% 100% 14.3% 51.4% 31.4% 100% 61 Gastric resection
Madsen11 Denmark 11 11 (100%) Median 46 100% 100% 45% NR 0% 90% 11 Healthy
Mancilla19 Chile 14 11 (78.5%) Mean 49 50% 100% 28.5% 64% 21.4% 64% 14 Healthy
Grigor’eva21 Russia 102 35 (34.3%) Mean 55 NR 70.6% NR NR 0% NR – –
Kumar22 India 68 48 (70.6%) Mean 33.6 32.3% 31.7% 35% 66% NR 66.2% 74 Healthy
Signoretti12 Italy 43 24 (55.8%) Mean 54 39.5% 39.5% 41.8% NR 0% 62.8% 43 Unspecific
GI complaints
Kim24 South
Korea
36 28 (77.8%) Mean 52.3 78.9% NR 66.6% 47.2% 0% 52% 49 Healthy
GI: gastrointestinal; NR: not reported; PEI: pancreatic exocrine insufficiency; PERT: pancreatic enzyme replacement therapy.
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I2¼ 77%. As far as regards the quality of the studies, six
of them were classified as of ‘high quality’ and the pooled
prevalence of SIBO for these studies was 41.5% (95% CI
15.6–73.2%) with an I2¼ 94%. In the three studies with
a lower quality score, the pooled estimate rate was as
high as 31.4% (95% CI 16.1–52.2%) with an I2¼ 40%.
Prevalence of SIBO in patients with CP
as compared with controls
There were seven case-control studies, containing 222
CP patients and 291 controls. One of the studies11 did
not report any diagnosis of SIBO among either cases
or controls. Therefore, the analysis comparing cases
and controls was performed on the remaining six stu-
dies, examining 211 cases and 280 controls. Four of
these studies employed GHBT, and two LHBT (see
details in Table 1). Four studies defined the controls
as healthy individuals,11,19,20,22,24 one study as subjects
with non-specific, non-chronic gastrointestinal com-
plaints,12 whilst two studies10,20 enrolled individuals
with previous history of gastric/duodenal resection20
and/or affected by primary immunodeficiency as con-
trols.10 The odds of a positive test for SIBO in CP
Table 2. Methods and protocols for the diagnosis of small intestine bacterial overgrowth (SIBO) employed in the evaluated studies.
First author
(reference) Test
Patients
(n)
Dose of
substrate
Duration
of the test
Sample
intervals Cut-off for the diagnosis of SIBO
Lembcke23 GHBT/14C-CGBT 12/20 50 g NR NR H2> 20 ppm compared to baseline
Casellas10 GHBT 15 50 g/250ml 180min 15min H2> 10 ppm compared to baseline
Trespi20 GHBT 35 50 g/250ml 180min 30min H2> 20 ppm compared to baseline
Madsen11 GHBT 11 NR 6 h 15min H2 12 ppm compared to baseline
Mancilla19 LHBT 14 25 mg 180min 10min H2> 20 ppm compared to baseline
or >22 in 60min
Grigor’eva21 LHBT 102 NR NR NR H2 20 ppm compared to baseline
Kumar22 GHBT 68 100 g/200ml 180min 15min H2 12 ppm compared to baseline
Signoretti12 GHBT 43 50 g/250ml 120min 20min H2 12 ppm compared to baseline
or >20 ppm at baseline
Kim24 LHBT 36 10 g 180min 15min H2 20 ppm or CH4 10 ppm compared
to baseline or H2 20 ppm or CH410 ppm
within 90min after lactulose load
14C-CGBT: 14C-cholylglycine breath test; CH4: methane; GHBT: glucose H2 breath test; H2: hydrogen; LHBT: lactulose H2 breath test; NR: not reported; ppm:
parts per million.
Study name Event rate and 95% CIStatistics for each study
-2,00 -1,00 1,00 2,000,00
Event
rate
Upper
limit Z-Value p-Value
Lower
limit
Madsen
Casellas 0,400 0,192 0,652 –0,769 0,442
0,063
0,030
0,000
0,000
0,013
0,026
0,000
0,719
0,254
–1,859
–2,170
–2,232
–0,360
–1,142
5,450
–3,539
–5,194
2,479
0,509
0,425
0,356
0,244
0,988
0,403
0,858
0,630
0,601
0,204
0,003
0,113
0,076
0,625
0,002
0,700
0,315
0,175
0,340
0,042
0,210
0,140
0,920
0,038
0,790
0,470
0,361
Trespi
Signoretti
Kumar
Mancilla
Lembcke
Grigoreva
Kim
Figure 2. Forest plot of the pooled prevalence of small intestine bacterial overgrowth in chronic pancreatitis in all the nine included
studies. Random-effects model demonstrating a pooled prevalence of 36% (95% confidence interval (CI) 17–60%) with considerable
heterogeneity (I2¼ 91%).
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patients compared with controls was 4.1 (95% CI 1.6–
10.4) (Figure 5), with I2¼ 59.7%. No publication bias
was found (Begg and Mazudmar Kendall’s tau¼ 0.4;
p¼ 0.2). The odds of a positive test for SIBO in CP
patients when considering only the studies that
employed GHBT was 2.8 (95% CI 1.2–6.8) with a
lower heterogeneity (I2¼ 32%).
Relation between symptoms and nutritional
status and SIBO, and response to treatment
Among the nine studies included in this meta-analysis,
five12,20–22,24 evaluated the differences between CP
patients with or without SIBO in terms of symptoms
and/or nutritional parameters. In the study by Trespi
and colleagues,20 patients with SIBO more frequently
complained diarrhoea as compared to those without
(73% vs 9%, p¼ 0.001). Grigor’eva et al.21 reported
that CP patients with SIBO, when compared to those
without, had a higher prevalence of pain caused by
bowel dysfunction (80.3% vs 45.2%; p< 0.001) and
duodenal hypertension (71.8% vs 41.9%; p< 0.01).
The rates of diarrhoea (67.6% vs 41.9%; p< 0.05),
flatulence (84.5% vs 41.9%; p< 0.001), nausea (57.7%
vs 35.9%; p< 0.05), and feeling of bitter taste in the
mouth (69% vs 45.2%; p< 0.05) were also significantly
higher in CP patients with SIBO.
Kim et al.24 also reported that CP patients with SIBO
were more often symptomatic, with significantly higher
symptom scores for hard stool, flatus and bloating.
Patients with production of both H2 and CH4 seemed
to experience more symptoms. In the same study, there
Study name Event rate and 95% CIStatistics for each study
-2,00 -1,00 1,00 2,000,00
Event
rate
Upper
limit Z-Value p-Value
Lower
limit
Madsen
Casellas 0,400 0,192 0,652 –0,769 0,442
0,063
0,030
0,000
0,000
0,026
0,000
–1,859
–2,170
–3,539
–5,194
–2,232
–3,918
0,509
0,425
0,356
0,244
0,403
0,345
0,204
0,003
0,113
0,076
0,002
0,127
0,340
0,042
0,210
0,140
0,038
0,217
Trespi
Signoretti
Kumar
Lembcke
Figure 3. Forest plot of the pooled prevalence of small intestine bacterial overgrowth in chronic pancreatitis in the six studies employing
glucose as substrate for the hydrogen breath test. Random-effects model demonstrating a pooled prevalence of 21.7% (95% confidence
interval (CI) 12.7–34.5%) with reduced heterogeneity (I2¼ 56%).
Study name
Madsen 0,042 0,003 0,425 –2,170 0,030
0,026
0,000
0,000
0,000
0,719
0,129
–3,539
–5,194
–2,232
–0,360
–1,519
5,450
0,356
0,244
0,403
0,858
0,630
0,576
0,113
0,076
0,002
0,700
0,315
0,081
0,210
0,140
0,038
0,790
0,470
0,257
Signoretti
Kumar
Lembcke
Grigoreva
Kim
Event
rate
Event rate and 95% CI
-2,00 -1,00 1,00 2,000,00
Upper
limit Z-Value p-Value
Lower
limit
Statistics for each study
Figure 4. Forest plot of the pooled prevalence of small intestine bacterial overgrowth in chronic pancreatitis in the six studies that did not
include patients who previously received surgery. Random-effects model demonstrating a pooled prevalence a 25.7% (95% confidence
interval (CI) 8.1–57.6%) with considerable heterogeneity (I2¼ 94%).
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were no differences between CP patients with or without
SIBO in terms of nutritional parameters. Kumar et al.22
and Signoretti et al.12 instead, found no difference
between patients with or without SIBO in terms of
symptoms. Signoretti et al.12 reported that Vitamin D
level showed a trend close to significance for being
lower in CP patients with SIBO as compared to those
without SIBO (15.9 ng/ml vs 25.2ng/ml, p¼ 0.08).
Only three of the nine studies included in this meta-
analysis evaluated the response to treatment and symp-
tom modification afterwards. Casellas et al.10 treated five
CP patients with SIBO with doxycycline or metronida-
zole, with a clinical response in two of them, as watery
diarrhoea disappeared in both. In the study by Kumar
et al.,22 33% of CP patients with PEI and persistent diar-
rhoea had SIBO, and were then treated with rifaximin
with improvement of the diarrhoea, although resolution
of SIBO by repeated GHBT was not documented. Trespi
et al.20 treated CP patients both either with or without
SIBO, with rifaximin. All patients with initial diagnosis
of SIBO turned SIBO-negative and had disappearance of
diarrhoea, while patients that had diarrhoea not asso-
ciated with SIBO had no response (p¼ 0.03).
Discussion
To our knowledge, this is the first meta-analysis
that investigated the prevalence of SIBO in patients
with CP. In the present study, data from nine publica-
tions were analysed, resulting in a pooled prevalence
of SIBO of 36% in CP patients, with a range between
14–92% and considerable heterogeneity. The preva-
lence of SIBO seems to depend on the type of test
used, with higher prevalence with LHBT than with
GHBT, and on the inclusion criteria for CP patients,
with higher positivity rates in studies including patients
who previously underwent surgery. When the preva-
lence of a positive test for SIBO was compared between
CP cases and controls, regardless of the test used, there
was a statistically significant increased risk for a
positive test result in CP patients. Furthermore, the
relationship between the presence and severity of symp-
toms and the diagnosis of SIBO in CP patients seemed
to vary across the different studies. A higher rate of
symptoms in patients with SIBO was reported in only
three of the five studies that examined this aspect, but
no data suggested that SIBO is more common in
patients not responding to PERT. On the other hand,
the treatment of SIBO with antibiotics in CP patients
seemed associated with clinical improvement.
The strengths of the present study include an
exhaustive literature search, rigorous statistical meth-
ods, and pooling of data to allow synthesis of all the
available published evidence examining the yield of
testing for SIBO in CP. The most obvious weaknesses
of the study, as with many systematic review and meta-
analysis, arise from the available evidence. Only a
limited number of studies, with relatively small
sample size were identified. All included studies were
cross-sectional or case-control studies conducted in
tertiary care centres and might therefore be subject to
a spectrum bias and include only more advanced cases.
Furthermore, all the included studies employed BTs as
diagnostic procedure for SIBO and none of them jeju-
nal aspirate and culture, which is often considered the
gold standard for the diagnosis.25 However, jejunal
aspirate and culture might not diagnose SIBO occur-
ring in the distal part of the small intestine.26
The findings of this meta-analysis suggest that about
one-third of CP patients are affected by SIBO. As we
anticipated that there might have been considerable
heterogeneity for this analysis, we decided to carry
out all analyses using the random-effects model, to pro-
vide the most conservative estimates, and to perform
sensitivity analysis for some variables. The substrate
used for the BT was found to be a significant factor
affecting both the rate of SIBO, as this is higher in
studies employing LHBT compared with GHBT, and
Study name
Odds
ratio
Lower
limit
Upper
limit Z-Value p-Value
0,01
Casellas 9,333 0,958 90,940 1,923
1,384
3,495
0,848
2,381
1,952
3,025 0,002
0,051
0,017
0,397
0,000
0,166
0,054
4,877
2999,916
5,069
101,184
6,163
10,497
0,761
9,521
0,526
1,566
0,996
1,652
1,926
1,632
12,586
2,478
4,164
169,000
Trespi
Mancilla
Signoretti
Kumar
Kim
0,1 1 10 100
Statistics for each study Odds ratio and 95% CI
Figure 5. Forest plot of the summary odds ratio (OR) for chronic pancreatitis and the risk of small intestine bacterial overgrowth (SIBO)
compared to controls. Random effects model demonstrating and OR of 4.1 (95% confidence interval (CI) 1.6–10.4) for a positive test.
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heterogeneity, which was lower when only studies with
GHBT were analysed (see Figures 2 and 3). These
results are in keeping with previous data27 and with
guidelines and expert opinions that suggest employing
glucose and not lactulose as substrate for H2 BT for the
diagnosis of SIBO.8,9 Interestingly, when an expert
working team8 analysed the available literature to
evaluate the accuracy of breath testing with either lac-
tulose and glucose as compared with jejunal aspirate,
the reported median sensitivity and specificity were of
62.5% and 81.8% for GHBT and 52.5% and 85.7% for
LHBT, with a diagnostic accuracy of 71.7% for glucose
and 55.1% for lactulose. This finding seemed similar in
patients with different disorders. A more recent study28
compared GHBT and LHBT to upper gut aspirate
culture in 80 patients with irritable bowel syndrome,
and found that BT employing glucose had a higher
accuracy (sensitivity 27%, specificity 100%), compared
with lactulose BTs considering either double peaks
(sensitivity 0%, specificity 98%) or early peak (sensitiv-
ity 33%, specificity 65%). However, the sensitivity of
the GHBT remains relatively low.
Not surprisingly, the rate of positive tests for
SIBO in CP patients was also higher in studies
that included patients that had previously undergone
surgical procedures. It is well known that resective sur-
gery of the gastrointestinal tract can cause SIBO,29
and such patients should be tested for this condition,
especially if symptomatic, independently from their
diagnosis of CP. A third factor that we considered
for sensitivity analysis was the quality of the studies.
However, most studies we have been able to analyse
had a high quality score, and quality did not seem
to influence the rate of SIBO or to determine
heterogeneity.
Data from the present study suggest that the risk of
SIBO is four times higher in patients with CP as com-
pared with controls. This estimate is slightly lower
when taking in consideration only studies that
employed glucose as substrate for H2 BT. The reasons
for the development of SIBO in CP patients might
include malabsorption of nutrients, previous surgery,
use of alcohol,30 of drugs such as proton pump inhibi-
tors31 or pain-killers affecting motility, and diabetic
neuropathy.32 At any rate, it is currently suggested to
test CP patients for SIBO only in cases with PEI not
responding to high doses of pancreatic enzymes.6,33
Interestingly, when we analysed data regarding symp-
toms and their relation with the presence of SIBO,
it was difficult to reach a straightforward conclusion,
as only some of the studies suggested that CP patients
with SIBO have more symptoms. Furthermore, there is
no evidence suggesting that SIBO is more common in
patients with CP and PEI who do not respond to high
doses of PERT, as no studies had a design of this kind.
As far as regards the treatment of SIBO, few studies
evaluated the effect of therapy, with data suggesting
that, as in other disorders,34 treatment with antibiotics
such as rifaximin might be effective in eradicating SIBO
and reducing symptoms.
In conclusion, the present study demonstrates that
SIBO is a rather frequent condition in patients with CP.
The results might suggest that all CP patients should be
screened for SIBO, irrespective of symptoms, as clinical
complaints due to SIBO might be confused with those
related with unresponsive steatorrhoea, possibly lead-
ing to a pointless increased dosage of PERT that
might result in increased costs and reduced compliance.
The studies evaluated in this meta-analysis differ
in terms of study design and study population defin-
ition. Therefore, we foresee the need for larger studies,
employing more rigorous and standardised methods,
such as jejunal aspirate culture and GHBT and CH4
breath test. These studies should be conducted in an
homogeneous setting of patients with CP and symp-
toms either under PERT or not, to clarify the role of
SIBO in CP, and the effect of its treatment in terms
of symptomatic response and possible beneficial effects
on nutritional parameters.
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